PMID: 7028540Jan 1, 1981Paper

Diabetic hypertriglyceridemia: evidence for three clinical syndromes

Diabetes
G M Reaven, M Greenfield

Abstract

Based on studies of both man and rat, it is proposed that at least three distinct syndromes of hypertriglyceridemia occur as the result of abnormalities of carbohydrate metabolism. We believe that these syndromes are the predictable results of the changes in plasma insulin and/or free fatty acid (FFA) concentration that occur in patients with impaired glucose tolerance (IGT), non-insulin-dependent diabetes mellitus (NIDDM), and insulin-dependent diabetes mellitus (IDDM). In patients with IGT the basic defect is postulated to be loss of normal insulin sensitivity, leading to compensatory hyperinsulinism, increased very low density lipoprotein (VLDL)-triglyceride (TG) secretion, and hypertriglyceridemia. In contrast, patients with NIDDM have ambient insulin concentrations that are "normal" in absolute terms, and in these subjects we believe that the elevated circulating FFA concentrations increase hepatic VLDL-TG secretion, which, in turn, is responsible for the hypertriglyceridemia. However, elevated FFA levels do not stimulate hepatic VLDL-TG secretion in insulin-deficient patients with IDDM, presumably because the livers of such individuals are not capable of responding to the increased FFA flux. In these subjects, the develop...Continue Reading

Citations

Sep 1, 1987·Diabetologia·M ModanA Lusky
Jan 1, 1996·Archives of Toxicology·M R LovatiC R Sirtori
Aug 31, 1993·Clinica Chimica Acta; International Journal of Clinical Chemistry·S SahekiK Uchida
Jun 1, 1996·Diabetes Research and Clinical Practice·G YoshinoT Kazumi
Nov 1, 1989·Medical Hypotheses·J R Field, L B Jeffcott
May 5, 2005·European Journal of Pharmacology·Masumi YoshidaMikio Ito
May 1, 1988·Baillière's Clinical Endocrinology and Metabolism
Jun 1, 2002·Journal of Diabetes and Its Complications·David B Huang, Philip Raskin
Oct 2, 1998·Journal of Clinical Pharmacy and Therapeutics·S Y WuJ C Chan
Nov 9, 2000·Clinical and Experimental Pharmacology & Physiology·Y YamasakiA Tanigami
Mar 1, 1999·Asia Pacific Journal of Clinical Nutrition·I K QuayeY Kido
Nov 1, 2001·Diabetes, Obesity & Metabolism·P Arner
Nov 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·C H WardenY D Chen
Sep 30, 2000·Assistive Technology : the Official Journal of RESNA·W A BaumanB J Kemp
Mar 18, 2003·Journal of Medicinal Food·Panam ParikhUma Iyer
Nov 11, 1999·Current Opinion in Lipidology·M EvansA Rees
Jan 1, 1994·The Journal of Clinical Investigation·M K HellersteinD Faix
Feb 21, 2002·Biological & Pharmaceutical Bulletin·Koji Hayashi, Mikio Ito
Mar 3, 2004·Biological & Pharmaceutical Bulletin·Masumi YoshidaMikio Ito
Jul 1, 1992·The British Journal of Nutrition·A O AkanjiE O Agbedana
Nov 17, 1994·Biochimica Et Biophysica Acta·J D Sparks, C E Sparks
Nov 1, 1991·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·S OikawaT Toyota
Jul 1, 1990·American Journal of Obstetrics and Gynecology·D SimonL Papoz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.